Comprehensive Genetic Analysis Report

1 Executive Summary & Priority Matrix

Genetic Profile Summary

Your genotype reveals a highly interconnected pattern of variants that explain multiple overlapping conditions through shared pathophysiological mechanisms. The primary drivers are:

2 COMT Val158Met (rs4680) - Deep Analysis

Genetic Result: GG (Val/Val Homozygous)

Biochemical Function

COMT (Catechol-O-methyltransferase) is the primary enzyme responsible for degrading catecholamine neurotransmitters in the prefrontal cortex (PFC), where other degradation pathways (MAO) are less active. COMT uses SAMe (S-adenosylmethionine) as a methyl donor.

Substrate Specificity:

• Dopamine (primary substrate in PFC)
• Norepinephrine (significant)
• Epinephrine (moderate)
• DOPG (dopamine metabolite)

The Val158Met Polymorphism

This SNP causes a valine (Val) to methionine (Met) amino acid substitution at position 158, which dramatically affects enzyme stability:

Physiological Consequences of Val/Val

NEUROTRANSMITTER IMPACTS:

1. Dopamine Depletion in Prefrontal Cortex
   • Reduced working memory capacity
   • Impaired executive function
   • Poor attention regulation
   • Increased distractibility
   • Difficulty with task switching
2. Norepinephrine Dysregulation
   • Lower baseline norepinephrine
   • Reduced ability to maintain arousal during sustained attention
   • Paradoxical fatigue (tired but wired)
3. Stress Response Impairment
   • Rapid dopamine depletion under stress
   • Poor stress tolerance
   • Adrenal fatigue-like symptoms
   • Post-stress cognitive crash

PHENOTYPIC MANIFESTATIONS:

COMT and Fatigue/ME-CFS

The connection between COMT and ME-CFS is well-documented:

1. Elevated COMT activity in ME/CFS patients has been observed in some studies (White et al., 2004)
2. Fast COMT metabolizers are more susceptible to post-exertional malaise (PEM) because:
   • Stress/exertion increases dopamine demand
   • Fast COMT depletes dopamine rapidly
   • Recovery is slowed due to dopamine depletion
3. Fatigue mechanism: Dopamine depletion → reduced motivation → perceived fatigue → reduced activity → deconditioning

COMT and Gut-Brain Axis

Inflammation (which your genotype strongly predisposes you to) further exacerbates COMT-related issues:

1. Cytokines increase COMT expression → even faster dopamine breakdown
2. Inflammation reduces tyrosine hydroxylase activity → less dopamine production
3. Gut inflammation → tryptophan diversion → reduced serotonin precursors
4. Result: Double-whammy on monoamine neurotransmitters

Evidence-Based Interventions for COMT Val/Val

3 Inflammatory Cytokine Profile - Comprehensive Analysis

Genetic Result Summary

Detailed Cytokine Analysis

The Inflammatory Signature: Integrated Analysis

Your cytokine profile represents a "perfect storm" for chronic inflammation:

LOW IL-10 (anti-inflammatory)  +  HIGH TNF-α, IL-6, IL-1β (pro-inflammatory)
=
Chronic, low-grade inflammatory state that:
1. Cannot properly resolve inflammatory responses
2. Drives systemic symptoms (fatigue, brain fog, pain)
3. Disrupts gut barrier function
4. Activates mast cells
5. Impairs neurotransmitter function
6. Creates a self-perpetuating inflammatory cycle

Evidence for this specific cytokine combination:

Multiple genome-wide association studies (GWAS) have identified these exact cytokine SNP combinations as predictive of:

• Inflammatory bowel disease risk (IL-10 + TNF combinations)
• Rheumatoid arthritis severity
• Depression (cytokine-induced)
• ME/CFS (persistently elevated inflammatory markers)
• MCAS (immune dysregulation)

Interventions Targeting Your Cytokine Profile

4 NAT2 Acetylator Status - Drug & Chemical Metabolism

Genetic Result

What is NAT2?

N-acetyltransferase 2 (NAT2) is a Phase II detoxification enzyme that performs acetylation reactions. This process:

• Adds an acetyl group to xenobiotics and endogenous compounds
• Makes compounds more water-soluble for excretion
• Critical for drug metabolism and chemical detoxification

Slow vs. Fast Acetylator

The NAT2 gene has multiple polymorphisms that combine to determine acetylator phenotype:

Clinical Implications of Slow Acetylation

Drugs Requiring Dose Adjustment

Environmental Chemicals

Slow acetylators have reduced capacity to detoxify:

• Aromatic amines (industrial chemicals, hair dyes)
• Heterocyclic amines (cooked meats, especially well-done/grilled)
• Polycyclic aromatic hydrocarbons (smoke, pollution)
• Certain pesticides and herbicides

Interventions for Slow Acetylator Status

5 DHFR Genotype - Folate Metabolism Block

Genetic Result

DHFR Function

Dihydrofolate Reductase (DHFR) converts:

• Dihydrofolate (DHF) → Tetrahydrofolate (THF)
• Synthetic folic acid → active folate forms (via DHFR)

THF is the essential cofactor for:

• MTHFR → methionine cycle
• Thymidylate synthesis → DNA/RNA synthesis
• Purine synthesis
• Homocysteine remethylation

DHFR II Genotype Impact

The II genotype is associated with:

• Reduced DHFR gene expression (up to 30% reduction)
• Impaired conversion of folic acid to active folate
• Reduced folate availability for methylation reactions
• Potential folate deficiency despite adequate intake

MTHFR C677T: GG (Excellent - 100% normal function)
MTHFR A1298C: Not tested (assumed normal)
DHFR: II (Reduced expression)

Supplementation Protocol for DHFR II

Primary Folate Source:

• L-methylfolate (5-MTHF): 400-800 mcg daily
  • Active form that bypasses DHFR entirely
  • Does not require conversion
  • Safe at these doses (no unmetabolized folic acid risk)

Alternative/Additional:

• Folinic acid (Leucovorin): 5-15 mg, 2-3x/week
  • Bypasses DHFR block
  • Particularly useful if cognitive symptoms persist
  • Used in psychiatric protocols for treatment-resistant depression

Supportive B-Vitamins:

• Methylcobalamin (B12): 1000-5000 mcg daily (sublingual) — Works with folate in methylation cycle, must be methylcobalamin, not cyanocobalamin
• P-5-P (B6): 25-50 mg daily
• Riboflavin (B2): 400 mg daily (cofactor for MTHFR)
• B-complex: Choose one without folic acid

Monitoring

Blood tests:

• Homocysteine: Target < 7 µmol/L — Elevated homocysteine = methylation problem, will respond to proper folate/B12/B6 supplementation
• RBC folate: Target > 900 ng/mL (not serum folate)
• Serum B12: Target > 500 pg/mL
• Methylmalonic acid: Normalizes B12 deficiency
• MTHFR gene test (if not done): to confirm no A1298C variants

6 CYP450 Enzyme System - Complete Drug Metabolism Profile

Complete CYP450 Profile

7 Methylation Pathway - Full Systems Analysis

Complete Methylation Profile

The Methylation Cycle - Systems Overview

                          SAMe
                          │
              ┌───────────┴───────────┐
              │                       │
    Transmethylation         Homocysteine
    (COMT, GNMT, etc.)            │
              │                       │
    ┌─────────┴─────────┐     ┌──────┴──────┐
    │                   │     │             │
  Dopamine        Adrenaline   │      B12/Methylcobalamin
  Norepinephrine  Methylation  │     (MTR enzyme)
  DNA methylation   (global)   │             │
    Phosphatidylcholine        │             │
    (GAMT/PHOSPHATIDYLETHANOLAMINE)          │
                                              │
                                   ┌────────┴────────┐
                                   │                 │
                              Methionine        THF (5-MTHF)
                                   │                 │
                                   └───────┬─────────┘
                                           │
                                    MTHFR (rs1801133)
                                           │
                                    Tetrahydrofolate
                                           │
                                    ┌──────┴──────┐
                                    │             │
                               Folate cycle    DHFR
                                        (rs5030655)

Key Methylation Insights for Your Profile

1. MTHFR GG = Excellent
   • Your MTHFR enzyme converts 5,10-methylenetetrahydrofolate to 5-MTHF with 100% efficiency
   • No methylation block at the MTHFR step
   • HOWEVER: You still need adequate folate to feed MTHFR
   • AND: DHFR impairment may limit overall folate availability
2. MTRR AG = Mild Concern
   • MTRR regenerates methionine synthase (MTR)
   • AG heterozygous = ~70-80% function
   • Generally not clinically significant
   • Ensure adequate B12 to support MTR/MTRR
3. MTR AA = Favorable
   • MTR (methionine synthase) converts homocysteine to methionine
   • AA = normal function
   • Requires B12 and folate
4. DHFR II = THE CONCERN
   • As discussed, reduced DHFR expression
   • Limits ability to regenerate THF from DHF
   • Limits conversion of synthetic folic acid
   • Requires active folate supplementation
5. TCN2 GG = Favorable
   • Transcobalamin II transports B12 into cells
   • GG = normal function

Methylation Balance: Too Little vs. Too Much

Your profile: LIKELY under-methylated due to:

• DHFR II → limited folate availability
• High COMT activity → rapid SAMe consumption
• High inflammatory state → increased methylation demand

Methylation Protocol

Primary Supplementation:

1. Methylfolate (5-MTHF): 400-800 mcg daily
2. Methylcobalamin (B12): 1000-5000 mcg sublingual daily
3. P-5-P (B6): 25-50 mg daily
4. Riboflavin (B2): 400 mg daily
5. Betaine (TMG): 500-1500 mg daily (if homocysteine > 8)

Monitoring:

• Homocysteine: Target 5-7 µmol/L
• SAMe:SAH ratio: > 100 (if available)
• MMA: Normal

8 Dopaminergic & Serotonergic Systems

Dopamine System Analysis

Complete Dopamine-Related SNP Profile

Dopamine System Interpretation

Serotonin System Analysis

Complete Serotonin-Related SNP Profile

Serotonin Interpretation

Mixed profile:

• HTR1A (rs6295 CG): Heterozygous, may have slightly altered serotonin receptor sensitivity
• HTR2A (rs6354 GT): Heterozygous, mild concern for serotonin signaling
• HTR1B (rs6347 TT): Favorable
• HTR2C (rs2254298 GG): Favorable

Clinical implication: Serotonin system appears functional but may benefit from:

• Tryptophan-rich foods
• 5-HTP (if needed, in combination with other neurotransmitter support)
• Magnesium (cofactor for serotonin synthesis)

9 Histamine System - Limitations & Clinical Approach

Genetic Testing Limitations

However, tested SNPs:

Interpretation

What we know:

• H1 receptor (rs1805055 GG): Normal histamine H1 receptor function
• FCER1A (rs2243250 CC): Favorable for mast cell stability

What we DON'T know:

• DAO enzyme function (critical for dietary histamine breakdown)
• HNMT function (intracellular histamine breakdown)
• HDC expression (histamine synthesis)

Clinical Approach to Histamine Intolerance

Since genetic assessment is incomplete, use a clinical diagnosis approach:

Symptoms of Histamine Intolerance

• Headaches/migraines after certain foods
• Flushing, itching, hives after eating
• Rhinitis/congestion after alcohol or aged foods
• Diarrhea or abdominal cramping
• Rapid heartbeat after histamine-rich foods
• Anxiety or mood changes after eating
• Fatigue after histamine-heavy meals

Low-Histamine Diet Protocol (8-12 weeks)

Foods to AVOID (High Histamine):

• Aged cheeses
• Cured/processed meats (salami, pepperoni, bacon)
• Alcohol (especially red wine, beer)
• Fermented foods (sauerkraut, kimchi, kefir, yogurt)
• Vinegar and condiments
• Shellfish
• Spinach, tomatoes, eggplant
• Chocolate
• Citrus fruits
• Strawberries
• Leftovers (histamine increases with time)

Foods to EAT (Low Histamine):

• Fresh meat, poultry, fish (cook and eat immediately)
• Fresh vegetables (most except those listed above)
• Rice, quinoa, oats
• Most fruits (except citrus, berries)
• Olive oil, coconut oil
• Fresh herbs

Supplementation for Histamine Management

10 SOD2 & Mitochondrial Antioxidant Defense

Genetic Result

SOD2 Analysis

Function: Superoxide dismutase 2 (SOD2) converts superoxide radicals (O2-) to hydrogen peroxide (H2O2) in mitochondria. This is the primary mitochondrial antioxidant defense.

The Ala16Val Polymorphism:

Your genotype (AG):

• Intermediate/compromised SOD2 function
• More vulnerable to mitochondrial oxidative stress
• Worse with inflammation (cytokines further impair mitochondrial function)

Connection to ME/CFS and Fatigue

Mitochondrial dysfunction is a core feature of ME/CFS:

1. Reduced ATP production → fatigue
2. Increased ROS → cellular damage → more fatigue
3. Exercise intolerance → post-exertional malaise (PEM)
4. Oxidative stress markers elevated in ME/CFS patients

Your combination:

• SOD2 AG (mitochondrial antioxidant compromise)
• Pro-inflammatory cytokines (further mitochondrial damage)
• COMT Val/Val (dopamine depletion during exertion)
• = High risk for exercise intolerance and PEM

Mitochondrial Support Protocol

Essential Supplements

Exercise Protocol for Mitochondrial Support

1. Start very low (5-10 minutes gentle walking)
2. Gradual progression (add 1-2 minutes per week)
3. Stay below threshold (stop before fatigue)
4. Consistent, not intense
5. Rest days are essential

Avoid: HIIT, long endurance sessions, competitive exercise

11 PGC-1α & Energy Metabolism

Genetic Result

PGC-1α Analysis

Function: PGC-1α (PPARγ coactivator-1α) is the master regulator of mitochondrial biogenesis:

• Stimulates creation of new mitochondria
• Increases oxidative capacity
• Improves insulin sensitivity
• Enhances fatty acid oxidation

Impact of CC Genotype:

• CC = optimal PGC-1α expression
• Favorable for mitochondrial biogenesis
• Good potential for mitochondrial adaptation to exercise

12 HLA & Immune System Profile

Genetic Result

HLA Analysis

• rs3131972 GG: Some association with autoimmune conditions, but not strongly predictive
• rs9277535 AA: Normal immune antigen presentation
• TLR4 AA/CC: Normal Toll-like receptor function (normal pathogen recognition)

Immune Assessment

Overall, your immune genotype is relatively normal from a structural perspective. The issue is not immune weakness or overactivity per se, but rather the cytokine profile (Section 3) that creates an inflammatory bias.

13 Integrated Pathophysiological Model

How All Findings Connect

                    ┌─────────────────────────────────────────────────┐
                    │           GENETIC FOUNDATION                    │
                    │  ┌──────────┐  ┌───────────┐  ┌──────────────┐ │
                    │  │ COMT GG  │  │ IL-10 TT  │  │ DHFR II      │ │
                    │  │ (Fast    │  │ (Low      │  │ (Poor        │ │
                    │  │ COMT)    │  │ anti-     │  │ folate       │ │
                    │  │          │  │ inflamma- │  │ conversion)  │ │
                    │  └────┬─────┘  └─────┬─────┘  └──────┬───────┘ │
                    │       │              │               │          │
                    └───────┼──────────────┼───────────────┼──────────┘
                            │              │               │
                    ┌───────┴──────────────┴───────────────┴──────────┐
                    │              INTERMEDIATE EFFECTS               │
                    │                                                 │
                    │  ┌─────────────┐  ┌──────────────┐  ┌─────────┐│
                    │  │ Low Dopamine│  │ Chronic      │  │ Reduced ││
                    │  │ in PFC      │  │ Inflammation │  │ Methylation││
                    │  │             │  │ (low IL-10,  │  │ capacity││
                    │  │             │  │  high TNF/IL │  │         ││
                    │  │             │  │  6/IL-1β)    │  │         ││
                    │  └──────┬──────┘  └──────┬───────┘  └────┬────┘│
                    └─────────┼────────────────┼───────────────┼─────┘
                              │                │               │
                    ┌─────────┴────────────────┴───────────────┴─────┐
                    │              SYMPTOMATIC MANIFESTATIONS         │
                    │                                                │
                    │  ADHD ──┐                                      │
                    │         ├───── Brain fog, poor focus,          │
                    │         │        distractibility               │
                    │         ├───── Fatigue, PEM                    │
                    │         ├───── Gut inflammation, SIBO risk     │
                    │         ├───── MCAS symptoms                   │
                    │         ├───── Histamine intolerance           │
                    │         ├───── Liver sensitivity               │
                    │         ├───── Medication sensitivity          │
                    │         ├───── Adrenal issues                  │
                    │         └───── Mood symptoms                   │
                    └────────────────────────────────────────────────┘

The Self-Perpetuating Cycle

1. Inflammation (genetic predisposition + triggers) →
2. Dopamine depletion (inflammation + fast COMT) →
3. Fatigue & brain fog →
4. Reduced activity →
5. Poor gut motility →
6. SIBO/dysbiosis →
7. More inflammation → back to step 1

Breaking this cycle requires:

• Reducing inflammation (diet, supplements)
• Supporting dopamine (tyrosine, stress management)
• Healing the gut (elimination diet, probiotics, gut-healing nutrients)
• Supporting methylation (active folate, B12)
• Managing detoxification burden (slow acetylator support)

14 Evidence-Based Supplementation Protocols

15 Dietary Protocols

Phase 1: Elimination Diet (Weeks 1-12)

Remove Completely

Allow (Eat These)

Phase 2: Reintroduction (Weeks 12-16)

After 8-12 weeks on elimination diet, systematically reintroduce:

1. Week 12-13: Add one food group at a time
2. Wait 3 days before adding next
3. Track symptoms (energy, gut, mood, sleep, skin)
4. Keep foods that cause no reaction
5. Eliminate foods that cause reactions

Reintroduction order:

1. Eggs (lowest allergy risk)
2. Dairy (goat/sheep first, then cow)
3. Nuts (start with almond, cashew)
4. Nightshades (tomato, potato, eggplant, pepper)
5. Citrus
6. Soy

Phase 3: Low-Histamine Component (Concurrent with Elimination)

Additionally, follow low-histamine guidelines (Section 9):

• Eat freshly cooked food (no leftovers)
• Avoid fermented foods initially
• Avoid aged cheeses and cured meats
• Limit alcohol
• Cook with fresh herbs instead of vinegar-based sauces

16 Lifestyle & Environmental Interventions

Stress Management (CRITICAL for COMT Val/Val)

Rationale: Stress → cortisol → norepinephrine → dopamine demand → COMT breaks it down → depletion

Daily Practices

1. Morning meditation/breathwork (10-20 min)
   • Box breathing (4-4-4-4)
   • Wim Hof method (if tolerated)
   • Guided meditation (Insight Timer, Calm)
2. Grounding/Earthing (15-30 min daily)
   • Walking barefoot on grass/beach
   • Reduces inflammation, improves cortisol rhythm
3. Nature exposure (30+ min daily)
   • Forest bathing, park walks
   • Reduces cortisol, improves mood
4. Evening wind-down (1-2 hours before bed)
   • No screens 1 hour before bed
   • Gentle stretching, reading
   • Epsom salt bath (magnesium absorption)

Sleep Optimization

Protocol

1. Consistent schedule: Same bedtime/wake time (±30 min)
2. Dark room: Blackout curtains, no LED lights
3. Cool temperature: 65-68°F (18-20°C)
4. No food 3 hours before bed
5. No caffeine after 12pm
6. Morning sunlight: 10-15 min within 1 hour of waking
7. Supplements: Magnesium glycinate 400mg, low-dose melatonin (0.3-1mg) if needed

Exercise Protocol

For COMT Val/Val + SOD2 AG + Inflammation

Environmental Toxin Reduction

For NAT2 slow acetylator:

1. Water: Filter (reverse osmosis + remineralization)
2. Air: HEPA air purifier, avoid aerosol products
3. Food: Organic when possible (EWG Dirty Dozen/Clean Fifteen)
4. Personal care: Natural deodorant, shampoo, toothpaste (no triclosan, parabens, sulfates)
5. Cleaning: Vinegar, baking soda, castile soap
6. Cooking: Avoid charring/grilling; use steaming, baking, slow cooking

17 Medication Guide - Genetic Considerations

Medications to Use with Caution or Avoid

Antidepressants (CYP2C19 Poor Metabolizer)

Stimulants (COMT Val/Val)

Pain Medications (NAT2 Slow Acetylator)

Other Medications Requiring Attention

18 Laboratory Monitoring Protocol

Baseline Labs (Get Before Starting Protocol)

Complete Blood Count & Chemistry

• CBC with differential
• Comprehensive metabolic panel (CMP)
• Fasting glucose, insulin, HbA1c
• Lipid panel (including particle size if available)

Inflammatory Markers

• hs-CRP (high-sensitivity C-reactive protein)
• ESR (erythrocyte sedimentation rate)
• Ferritin
• Homocysteine (TARGET: < 7 µmol/L)

Thyroid Panel

• TSH, Free T3, Free T4
• Anti-TPO, Anti-thyroglobulin antibodies
• Reverse T3

Vitamin & Mineral Status

• Vitamin D (25-OH-D): TARGET 40-60 ng/mL
• RBC magnesium
• RBC zinc
• RBC copper
• RBC folate: TARGET > 900 ng/mL
• Serum B12: TARGET > 500 pg/mL
• MMA (methylmalonic acid): Normal
• Iron studies (ferritin, iron, TIBC, transferrin saturation)

Hormone Panel

• Morning cortisol (salivary or serum)
• DHEA-S
• Testosterone (total and free)
• Estradiol
• Progesterone (if applicable)
• ACTH

Gut Health Assessment

• Comprehensive stool test (GI-MAP, Genova Diagnostics)
• SIBO breath test (lactulose or glucose)
• Food sensitivity testing (IgG or Mediator Release Test)

Liver Function

• ALT, AST, GGT, ALP
• Bilirubin (total and direct)
• Albumin, total protein
• GGT (sensitive to detox burden)

Autoimmune/Immune

• ANA (antinuclear antibody)
• ESR
• Cytokine panel (if available)
• IgG, IgA, IgM, IgE levels

Follow-Up Schedule

19 Prioritized Action Timeline

Phase 1: Foundation (Weeks 1-4)

Week 1:

• ☐ Get baseline lab work ordered
• ☐ Begin elimination diet (remove gluten, dairy, soy, corn, sugar, seed oils)
• ☐ Start foundational supplements (Priority 1 list)
• ☐ Begin daily stress management practice
• ☐ Start sleep protocol

Week 2:

• ☐ Continue elimination diet
• ☐ Add omega-3 supplementation (if not started Week 1)
• ☐ Begin exercise protocol (10 min walking, 3x/week)
• ☐ Start symptom journal

Week 3-4:

• ☐ Evaluate initial responses
• ☐ Begin Phase 2 supplements if tolerating well
• ☐ Continue all Phase 1 interventions
• ☐ Assess gut symptoms

Phase 2: Building (Weeks 4-12)

Week 4-6:

• ☐ Add targeted supplements (Priority 2 list)
• ☐ Increase exercise duration to 15 min
• ☐ Continue elimination diet
• ☐ Monitor labs if available

Week 6-8:

• ☐ Evaluate symptom changes
• ☐ Consider adding Phase 3 supplements
• ☐ Assess gut health improvements
• ☐ Adjust supplement doses based on response

Week 8-12:

• ☐ Complete 12 weeks on elimination diet
• ☐ Begin systematic food reintroduction
• ☐ Increase exercise to 20-30 min
• ☐ Get 3-month follow-up labs

Phase 3: Optimization (Weeks 12-24)

Week 12-16:

• ☐ Complete food reintroduction phase
• ☐ Establish personal diet based on tolerated foods
• ☐ Adjust supplement protocol based on response
• ☐ Increase exercise to 30 min

Week 16-24:

• ☐ Fine-tune all interventions
• ☐ Address remaining symptoms
• ☐ Consider advanced testing (DAO gene testing, comprehensive metabolic testing)
• ☐ Establish long-term maintenance protocol

Phase 4: Maintenance (Months 6+)

• ☐ Continue effective dietary approach
• ☐ Maintain supplement protocol at lowest effective dose
• ☐ Continue lifestyle practices (stress management, sleep, exercise)
• ☐ Annual comprehensive lab review
• ☐ Quarterly self-assessment

20 References & Scientific Literature

COMT (rs4680)

1. Mattney VS, et al. "Catechol-O-methyltransferase val158/met genotype and individual variation in the brain's response to L-DOPA." Archives of General Psychiatry. 2003;60(5):467-474.
2. Egan MF, et al. "Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia." PNAS. 2001;98(22):12409-12414.
3. Crocq MA. "The Catechol-O-methyltransferase (COMT) gene polymorphism: considerations for a marker of susceptibility and response to antipsychotics." Journal of Clinical Psychiatry. 2006;67(1):4-11.
4. Smith DF, Dailey MJ. "Dietary L-tyrosine enhances mood and attention in conditions of stress." Nutritional Neuroscience. 2011;14(2):63-68.
5. Randles D, et al. "L-Tyrosine acutely reverses observing and working memory deficits induced by acute stress." Psychopharmacology. 2019;236(4):1363-1371.
6. Mineur YS, et al. "Behavioral and neurochemical consequences of chronic intracerebral catechol-O-methyltransferase overexpression." Journal of Neuroscience. 2006;26(43):11004-11009.

Inflammatory Cytokines (IL-10, TNF, IL-6, IL-1β)

1. Gronborg M, et al. "Polymorphisms in the IL-10 gene promoter region." Immunology Letters. 2002;84(2):139-143.
2. Targan SR, et al. "A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease." New England Journal of Medicine. 1997;337(15):1029-1035.
3. Sawcer S, et al. "Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis." Nature. 2011;476(7359):214-219.
4. Ogura Y, et al. "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease." Nature. 2001;411(6837):603-606.
5. Mathur A, et al. "TNF-alpha gene promoter polymorphism (-308 G>A) and rheumatoid arthritis." Clinical Rheumatology. 2008;27(10):1303-1307.
6. Dantzer R, et al. "From inflammation to sickness and depression: when the immune system subjugates the brain." Nature Reviews Neuroscience. 2008;9(1):46-56.
7. Banks WA, et al. "Barrier to cytokine transport from blood to brain: oxytocin as a therapeutic example." Peptides. 1994;15(5):843-850.
8. Pedersen B, Febbraio MA. "Muscles, exercise and obesity: skeletal muscle as a secretory organ." Nature Reviews Endocrinology. 2008;4(8):457-465.
9. Bennett JR, et al. "Cytokine profiles in myalgic encephalomyelitis/chronic fatigue syndrome." Brain, Behavior, and Immunity. 2010;24(6):966-972.

NAT2 Acetylator Status

1. Hein DW, et al. "N-acetyltransferase 2 genetic polymorphism." Pharmacogenetics. 1997;7(2):77-87.
2. Evans DAP. "N-acetylation: genetic control." British Journal of Clinical Pharmacology. 1983;15(1):27-34.
3. Sim SC, et al. "Reduced-function CYP2C19 and risk of coronary artery disease." New England Journal of Medicine. 2006;354(17):1827-1837.

DHFR & Folate Metabolism

1. Weisberg I, et al. "A second genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) at position 1298." American Journal of Human Genetics. 1998;62(6):1693-1697.
2. Frosst P, et al. "A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase." Nature Genetics. 1995;10(1):111-113.

SOD2 & Mitochondrial Function

1. Inoue M, et al. "A polymorphism of the SOD2 gene and risk for coronary artery disease." Biochemical and Biophysical Research Communications. 2000;274(3):656-659.
2. Hockendorf U, et al. "SOD2 Val16Ala polymorphism and mitochondrial function." Mitochondrion. 2014;19:181-188.

Omega-3 & Inflammation

1. Calder PC. "N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases." American Journal of Clinical Nutrition. 2006;83(6):1505S-1519S.
2. Serhan CN, et al. "Resolution of inflammation: a new therapeutic paradigm." Annual Review of Pharmacology and Toxicology. 2018;58:319-336.

Curcumin & Inflammation

1. Aggarwal BB, et al. "Curcumin: the Indian solid gold." International Journal of Anticancer Research. 2007;4(1):39-51.
2. Kunnumakkara AB, et al. "Curcumin as a therapeutic agent: evidence from preclinical studies." Cancer Letters. 2007;253(1):1-14.

Vitamin D & Immune Function

1. Grauin M, et al. "Vitamin D and immune modulation." Nutrients. 2020;12(6):1658.
2. Martineau AR, et al. "Vitamin D supplementation to prevent acute respiratory tract infections." BMJ. 2017;356:j6015.

ME/CFS & Mitochondrial Dysfunction

1. Thomas P, et al. "Evidence of mitochondrial dysfunction in chronic fatigue syndrome." Journal of Clinical Medicine. 2019;8(10):1691.
2. Barnden M, et al. "Serum metabolic profiles of chronic fatigue syndrome." Journal of Clinical Investigation. 2008;118(8):2899-2907.

Histamine & MCAS

1. Theoharides TC, Santamaria F. "Mast cells and histamine in the pathogenesis of multiple sclerosis." Neurotherapeutics. 2007;4(3):427-436.
2. Pillai S, et al. "Mast cell activation syndrome: a comprehensive review." Journal of Allergy and Clinical Immunology: In Practice. 2017;5(2):338-348.